Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Clin Oncol. 2009 Dec;6(12):679-80. doi: 10.1038/nrclinonc.2009.170.

Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?

Author information

  • 1Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.


Sunitinib is a standard first-line therapy for patients with advanced or metastatic clear-cell renal cell carcinoma. in an expanded-access study, sunitinib has demonstrated clinical benefit with an acceptable safety profile in a population of patients that is representative of those seen in clinical practice.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk